伊立替康联合卡培他滨治疗晚期结直肠癌的临床观察 |
| |
引用本文: | 张明奎,蒋华,孙运良.伊立替康联合卡培他滨治疗晚期结直肠癌的临床观察[J].实用肿瘤学杂志,2009,23(5):451-453,467. |
| |
作者姓名: | 张明奎 蒋华 孙运良 |
| |
作者单位: | 1. 江苏省连云港市赣榆县人民医院肿瘤科,赣榆,222100 2. 江苏省连云港市第二人民医院肿瘤科 |
| |
摘 要: | 目的观察伊立替康联合卡培他滨治疗晚期结直肠癌的疗效和安全性。方法回顾性分析62例复发或转移性结直肠癌患者,接受伊立替康联合卡培他滨治疗:伊立替康125mg/m^2 d1、d8、d15静脉滴注90min;卡培他滨(希罗达)2500mg/m^2,分早晚2次,第1—14天,每28天重复。治疗至少2个周期,按照WHO标准进行疗效和不良反应评价,并观察至疾病进展时间及总生存期。结果62例患者中,可评价疗效的有59例。其中一线治疗28例,RR42.8%,DCR71.4%,TTP 8.6个月,MST18.8个月;二线治疗31例,RR32.3%,DCR61.2%,TTP 7.2个月,MST13.2个月。不良反应主要为恶心与呕吐、迟发性腹泻、粒细胞减少,多为Ⅰ-Ⅱ度,且一线和二线治疗的不良反应无统计学差异。结论伊立替康联合卡培他滨治疗晚期结直肠癌疗效高,不良反应可耐受,值得扩大样本进一步观察。
|
关 键 词: | 伊立替康 卡培他滨 晚期结直肠癌 |
Clinical observation on irinotecan and capecitabine in the treatment of advanced or mestastatic colorectal cancer |
| |
Institution: | ZHANG Mingkui,JIANG Hua,SUN Yurdiang(1. Department of Oncology, The People's Hospital of Ganyu County, Ganyu 222100 ; 2. Department of Oncology, The Second People's Hospital of Liangyungang) |
| |
Abstract: | Objective To evaluate the efficacy and safety of irinotecan ( CPT - 11 ) combined capecitabine for patients with advanced or metastatic colorectal cancer. Methods Sixty - two patients with histologically proven advanced colorectal cancer received irinotecan 125 mg/m^2 on day 1,8,15 and capecitabine 2 500 mg/( m^2·d)as an intermitent regimen on day 1 to 14. The regimen was repeated every 4 weeks and efficacy and toxicity were evaluated after 2 cycles. The efficacy and safety were assessed on the basis of WHO evaluation standard of objective therapeutic effect for solid tumor. Results Fifty - nine patients were assessable for responses,including twenty - eight patients received the regimen as the first line chemotherapy and thirty - one patients as the second line chemotherapy. RR was 42.8% ,DCR was 71.4% ,TIP were 8.6 months and MST were 18.8 months in the first line chemotherapy. RR was 32.3% ,DCR was 61.2% ,TIP were 7.2 months and MST were 13.2 months in the second line chemotherapy. Dose limiting toxicity was delayed diarrhea and neutropenia. Most of them were Ⅰ/ Ⅱ degree and tolerable. There was no death during the treatment. Conclusion The combination chemotherapy of irinotecan with capecitabine is an active and tolerable regimen for advanced colorectal cancer. |
| |
Keywords: | Irinotecan Capecitabine Aadvanced colorectal cancer |
本文献已被 维普 万方数据 等数据库收录! |
|